指南与共识重症综合管理与镇静镇痛心脑血管急症

重型急性脑损伤临床试验参与者的不良事件登记:一项德尔菲共识研究

Adverse events registration in clinical trial participants with severe acute brain injury: a Delphi consensus study.
指南 / 共识 · Acta Neurochir (Wien) · 2025-12-22
一句话结论由10名北欧神经重症专家通过两轮德尔菲流程,形成含28项不良事件的标准化登记工具,用于重型急性脑损伤临床试验中不良事件的记录。

该研究旨在为重型急性脑损伤临床试验参与者开发标准化不良事件登记表,采用结构化德尔菲流程,由北欧国家重症监护、神经外科或神经内科临床专家进行两轮反馈。第一轮发放含25条重症监护与重型急性脑损伤相关不良事件建议定义的问卷,根据反馈修订后第二轮再次发放。德尔菲小组由10名专科医师组成,最终28项不良事件中27项达成共识(定义为≥70%同意),谵妄在第二轮未达共识但修订后保留于登记工具。最终登记工具包含28项不良事件,作者意图通过标准化记录提高临床试验伤害报告的透明度、准确性和一致性。

要点

  • 德尔菲小组由10名北欧重症监护、神经外科或神经内科专科医师组成,通过两轮反馈形成共识。
  • 共识定义为≥70%同意,最终28项不良事件中27项达成共识,谵妄在第二轮未达共识但修订后保留于工具中。
  • 最终登记工具包含28项适用于重型急性脑损伤患者的不良事件,用于临床试验中伤害报告。
  • 作者认为该工具有望通过标准化记录提高临床试验的整体质量。

适用人群与场景

  • 重型急性脑损伤临床试验参与者。
  • 德尔菲小组为来自北欧国家的10名专科医师,具有重症监护、神经外科或神经内科经验。

诊断标准与关键阈值

  • 德尔菲共识定义为≥70%同意。
  • 最终28项不良事件中27项达到共识(≥70%同意);谵妄在第二轮未达共识,修订后保留于登记工具。

研究设计与关键结果

  • 研究为德尔菲共识研究,德尔菲小组由10名北欧专科医师组成,进行两轮反馈。
  • 第一轮问卷含25条重症监护与重型急性脑损伤相关不良事件建议定义,根据反馈修订后第二轮发放修订版登记表。
  • 最终登记工具包含28项不良事件;27项达成共识(≥70%同意),谵妄未达共识但修订后保留。

证据类型、等级与局限

  • 证据类型:德尔菲共识研究。
  • 共识阈值:≥70%同意。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为该工具通过标准化记录,有望提高临床试验中伤害报告的透明度、准确性和一致性,并可能改善临床试验的整体质量。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Understanding the adverse effects of an intervention is important for evaluating its overall effect. Clinical trials mainly focus on the benefits of interventions with a risk of overlooking potential harms. Additionally, patients with severe acute brain injury frequently experience adverse events from other causes, which complicates the recording of harms in trials involving such participants. In this study, we developed a standardized registration form for recording adverse events in trial participants with severe acute brain injury using a structured Delphi process.

METHODS: After developing the tool, we employed a Delphi process comprising two rounds of feedback from clinical experts in Nordic countries. In the first round, the Delphi panel received a questionnaire with a preliminary registration form, consisting of a list of 25 suggested definitions for adverse events relevant in the context of intensive care and severe acute brain injury. Based on feedback from the Delphi panel, we revised the tool and sent the revised registration form as a questionnaire in the second Delphi round.

RESULTS: The Delphi panel consisted of 10 specialist physicians with experience in intensive care, neurosurgery or neurology. Consensus on the definition of an adverse event (defined as ≥ 70% agreement) was achieved for 27 out of the resulting 28 adverse events; for one adverse event, delirium, the level of agreement did not reach consensus in the second Delphi round; however, following revision, it was retained in the registration tool. The final version of the registration tool consisted of 28 adverse events for patients with severe acute brain injury.

CONCLUSION: A new tool for registration of adverse events and reactions in trial participants with severe acute brain injury was reviewed and refined by a Delphi panel of 10 Nordic neurocritical-care experts. The intention is to enhance the transparency, accuracy and consistency of reporting harms in clinical trials. Through thorough and standardized recording, the tool has the potential to improve the overall quality of clinical trials.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

参考来源

  1. Andreasen TH, Riberholt CG, Fenger AW, et al. Adverse events registration in clinical trial participants with severe acute brain injury: a Delphi consensus study. Acta Neurochir (Wien). 2025. PMID: 41428104. doi:10.1007/s00701-025-06724-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。